Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lyseng-Williamson, Katherine A.
Text and Data Mining valid from 2019-01-04
4 January 2019
21 February 2019
Paragraph 1, Sentences 1 and 2: the following text, which previously read: